1型人类免疫缺陷病毒逆转录酶第190位的突变通过模板引物与第74和75位的突变相互作用。
A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer.
作者信息
Boyer P L, Gao H Q, Hughes S H
机构信息
ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, Maryland 21702-1201, USA.
出版信息
Antimicrob Agents Chemother. 1998 Feb;42(2):447-52. doi: 10.1128/AAC.42.2.447.
Abstract
We have analyzed amino acid substitutions at position G190 in the reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1). The mutation G190E, which is responsible for resistance to certain nonnucleoside inhibitors, results in RT that has significantly less polymerase activity and that is less processive than wild-type RT. Its kinetic profile with respect to dGTP and poly(rC).oligo(dG) is significantly altered compared to that of wild-type RT. The combination of either of the mutations L74V or V75I with the G190E mutation appears to be compensatory and mitigates many of the deleterious effects of the G190E mutation.
摘要
我们分析了1型人类免疫缺陷病毒（HIV-1）逆转录酶（RT）中G190位点的氨基酸替代情况。导致对某些非核苷抑制剂耐药的G190E突变，会使RT的聚合酶活性显著降低，且持续性低于野生型RT。与野生型RT相比，其关于dGTP和聚（rC）·寡聚（dG）的动力学特征发生了显著改变。L74V或V75I这两种突变中的任何一种与G190E突变的组合似乎具有补偿作用，并减轻了G190E突变的许多有害影响。
相似文献
1
A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer.
Antimicrob Agents Chemother. 1998 Feb;42(2):447-52. doi: 10.1128/AAC.42.2.447.
2
A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation.
Biochemistry. 1996 Jul 30;35(30):9737-45. doi: 10.1021/bi9600308.
3
Enhanced binding of azidothymidine-resistant human immunodeficiency virus 1 reverse transcriptase to the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer.
J Biol Chem. 1998 Jun 5;273(23):14596-604. doi: 10.1074/jbc.273.23.14596.
4
Mechanistic insights into the role of Val75 of HIV-1 reverse transcriptase in misinsertion and mispair extension fidelity of DNA synthesis.
J Mol Biol. 2008 Feb 1;375(5):1234-48. doi: 10.1016/j.jmb.2007.11.021. Epub 2007 Nov 17.
5
Analysis of HIV-2 RT mutants provides evidence that resistance of HIV-1 RT and HIV-2 RT to nucleoside analogs involves a repositioning of the template-primer.
J Mol Biol. 1997 May 9;268(3):648-54. doi: 10.1006/jmbi.1997.0927.
6
Mutations at amino acid positions 63, 189, and 396 of human immunodeficiency virus type 1 reverse transcriptase (RT) partially restore the DNA polymerase activity of a Trp229Tyr mutant RT.
Virology. 2001 Aug 15;287(1):143-50. doi: 10.1006/viro.2001.1032.
7
Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
AIDS Res Hum Retroviruses. 1994 Aug;10(8):939-46. doi: 10.1089/aid.1994.10.939.
8
Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5 "- (4"-amino-1",2"-oxathiole-2",2"-dioxide)thymine (TSAO-T).
J Biol Chem. 1992 Jun 15;267(17):11831-8.
9
Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
J Virol. 2004 Sep;78(18):9987-97. doi: 10.1128/JVI.78.18.9987-9997.2004.
10
Dominance of the E89G substitution in HIV-1 reverse transcriptase in regard to increased polymerase processivity and patterns of pausing.
J Biol Chem. 1998 Aug 21;273(34):21918-25. doi: 10.1074/jbc.273.34.21918.
引用本文的文献
1
Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.
Nucleic Acids Res. 2016 Mar 18;44(5):2310-22. doi: 10.1093/nar/gkw060. Epub 2016 Feb 4.
2
Variation of human immunodeficiency virus type-1 reverse transcriptase within the simian immunodeficiency virus genome of RT-SHIV.
PLoS One. 2014 Jan 31;9(1):e86997. doi: 10.1371/journal.pone.0086997. eCollection 2014.
3
Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.
J Antimicrob Chemother. 2014 Jan;69(1):12-20. doi: 10.1093/jac/dkt316. Epub 2013 Aug 9.
4
L74V increases the reverse transcriptase content of HIV-1 virions with non-nucleoside reverse transcriptase drug-resistant mutations L100I+K103N and K101E+G190S, which results in increased fitness.
J Gen Virol. 2013 Jul;94(Pt 7):1597-1607. doi: 10.1099/vir.0.050914-0. Epub 2013 Mar 27.
5
A Leu to Ile but not Leu to Val change at HIV-1 reverse transcriptase codon 74 in the background of K65R mutation leads to an increased processivity of K65R+L74I enzyme and a replication competent virus.
Virol J. 2011 Jan 21;8:33. doi: 10.1186/1743-422X-8-33.
6
The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.
Virology. 2010 Jul 5;402(2):228-37. doi: 10.1016/j.virol.2010.03.018. Epub 2010 Apr 18.
7
Comparative analysis of in vitro processivity of HIV-1 reverse transcriptases containing mutations 65R, 74V, 184V and 65R+74V.
Antiviral Res. 2009 Sep;83(3):317-23. doi: 10.1016/j.antiviral.2009.06.002. Epub 2009 Jun 23.
8
Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.
AIDS Res Hum Retroviruses. 2008 Oct;24(10):1291-300. doi: 10.1089/aid.2007.0244.
9
Bayesian network analyses of resistance pathways against efavirenz and nevirapine.
AIDS. 2008 Oct 18;22(16):2107-15. doi: 10.1097/QAD.0b013e32830fe940.
10
Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase.
Retrovirology. 2008 Feb 13;5:20. doi: 10.1186/1742-4690-5-20.
本文引用的文献
1
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
N Engl J Med. 1997 Sep 11;337(11):734-9. doi: 10.1056/NEJM199709113371102.
2
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
N Engl J Med. 1997 Sep 11;337(11):725-33. doi: 10.1056/NEJM199709113371101.
3
In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097.
Virology. 1997 Apr 28;231(1):112-8. doi: 10.1006/viro.1997.8513.
4
Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms.
Structure. 1996 Jul 15;4(7):853-60. doi: 10.1016/s0969-2126(96)00091-3.
5
A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation.
Biochemistry. 1996 Jul 30;35(30):9737-45. doi: 10.1021/bi9600308.
6
(Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes.
J Virol. 1996 Jun;70(6):3698-705. doi: 10.1128/JVI.70.6.3698-3705.1996.
7
Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants.
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):34-8. doi: 10.1073/pnas.93.1.34.
8
Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents.
Antimicrob Agents Chemother. 1993 Jun;37(6):1207-13. doi: 10.1128/AAC.37.6.1207.
9
HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.
Science. 1995 Jan 27;267(5197):483-9. doi: 10.1126/science.7824947.
10
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.
Nature. 1995 Jan 12;373(6510):123-6. doi: 10.1038/373123a0.
Zotero 插件